NCT01138618已完成不适用
Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 85
- 试验地点
- 6
- 主要终点
- Pain sensation
研究概览
简要总结
Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine
研究设计
- 研究类型
- Observational
- 观察模型
- Case Crossover
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Treated with clozapine
- •Compliant with blood monitoring
- •Willing to give informed consent
排除标准
- •Prior case of agranulocytosis
结局指标
主要结局
Pain sensation
时间窗: Monthly for four months
Pain sensation was measured using a visual analog scale (VAS)
次要结局
- The benefits of CHEMPAQ(Monthly for four months)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
4 期
Clozapine Plasma Levels and the Relationship to the Genetic Polymorphism in Shizophrenic PatientsSchizophreniaNCT01663077Tirat Carmel Mental Health Center20
已完成
不适用
Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)SchizophreniaNCT02404155University of Maryland, Baltimore274
已完成
不适用
Prevalence of Sialorrhea in Patients Treated With ClozapineClozapine Adverse ReactionQuality of LifeSialorrheaNCT04197037Parc de Salut Mar129
已完成
不适用
Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)SchizophreniaNCT00753051Khon Kaen University18
已完成
4 期
Treatment Strategy for Refractory Schizophrenia: Drug Interaction Between Clozapine and FluvoxamineSchizophreniaNCT01401491Taipei Medical University Hospital80